Company overview
UEN
199705347C
Name
Novo Nordisk Asia Pacific Pte Ltd
Former names
Novo Nordisk Health Care (Asia Pacific)
Entity type
Local Company
UEN Issue Date
1 August 1997
Secondary SSIC Code
70201
Status
Dissolved - Members Voluntary Winding Up
Incorporation date
1 August 1997
Address
238A, THOMSON ROAD, #16-06/08, NOVENA SQUARE
Postal Code
307684
Country
Singapore
Primary goods traded
| Data Source | HS Code | Description | Buyer | Buyer Country | Seller | Seller Country | ||
|---|---|---|---|---|---|---|---|---|
| 16 September 2025 | PH | 30043100000 | Ozempic 1Mg 1Pc. With Nf Plus 4Pcs. - 123,440 Ea | Novo Nordisk Pharmaceuticals Philippines | PH | Novo Nordisk As | $8,845,820.36 | |
| 26 April 2022 | RU | 3004900002 | Medicines Not Containing Antibiotics, Hormones, Alkaloids, Vitamins, Iodine Or Iodine Compounds: Saxendar (Liraglutide) Solution For Subcutaneous Introduction 6 Mg / Ml (Cartridge In Syringe-Pen) 3 Mlh3 (Pack. Cart.) - 51360 Pack., Series Do, Mp5b03 | Novo Nordisk Llc | RU | Novo Nordisk As | $7,485,030.00 | |
| 20 July 2022 | RU | 3004310000 | Medicines For Medical Use Packed In Dosage Forms Not Packed For Retail, Not For Veterinary: | Novo Nordisk Llc | RU | Novo Nordisk As | $6,150,840.00 | |
| 24 November 2022 | RU | 3004310000 | Medicines For Medical Use Packed In Dosage Forms Not Packed For Retail, Not For Veterinary: | Novo Nordisk Llc | RU | Novo Nordisk As | $5,837,190.00 | |
| 12 March 2018 | RU | 2937120000 | Insulin And Its Salts. Pharmaceutical Substance. Is Intended For The Production Of Drugs For Medical Use (And Exactly: Production Of A Ready Dosage Form Of Solutions And Suspensions For Subcutaneous And Intravenous Administration, Insulin De | Novo Nordisk Llc | Novo Nordisk As | $5,708,443.90 | ||
| 27 March 2025 | PH | 30043100000 | Ozempic 1.5 Ml 0.5 Mg With Nf Plus 4 Pcs - 79,715 Ea | Novo Nordisk Pharmaceuticals Philippines | PH | Novo Nordisk As | $5,687,858.45 | |
| 21 October 2022 | RU | 3004310000 | Medicines For Medical Use Packed In Dosage Forms Not Packed For Retail, Not For Veterinary: | Novo Nordisk Llc | RU | Novo Nordisk As | $5,532,080.00 | |
| 16 July 2018 | RU | 2937120000 | Insulin And Its Salts. Pharmaceutical Substance. Intended For Production Of Medicinal Products For Medical Use (And Exactly: Production Of A Ready Dosage Form Of Solutions And Suspensions For Subcutaneous And Intravenous Administration, Primary Package) Not For Retail, Does Not Contain Alcohol, Not For Veterinary Medicine: Insulin Aspart, Crystalline Powder. Series Gq1ahp046. Valid Until 14.02.2022 Register Number: Фс-000844 Dated 05.22.17 Insulin Detemir, Crystalline Powder. Series Gdfdhp217. Valid Until 08/20/2022 Register Number: Фс-001313 Of 01/14/16 Insulin Detemir, Crystalline Powder. Series Gdfdhp218. Valid Until 21.08.2022 Register Number: Фс-001313 Of 14.01.16 Insulin Detemir, Crystalline Powder. Series Gdfdhp227. Valid Until 08/28/2022 Register Number: Фс-001313 Of 01/14/16 | Novo Nordisk Llc | RU | Novo Nordisk As | $5,148,870.39 | |
| 25 August 2021 | RU | 2937120000 | Insulin And Its Salts.â Pharmaceutical Substance.â Prepared For The Production Of Medicinal Products For Medical Use | Novo Nordisk Llc | RU | Novo Nordisk As | $4,871,320.00 | |
| 25 August 2020 | RU | 2937120000 | Insulin And Its Salts. Pharmaceutical Substance. Intended For The Production Of Drugs For Medical Use (And That Is: Production Of A Ready Dosage Form Of Solutions And Suspensions For Subcutaneous And Intravenous Administration | Novo Nordisk Llc | RU | Novo Nordisk As | $4,860,521.05 |
| Partner | Type | Total Value | Percentage |
|---|---|---|---|
| PT Beta Pharmacon | buyer | $348,291,417 | 25.51% |
| PT Ferron Par Pharmaceuticals | buyer | $64,527,156 | 4.73% |